Form 4: Celularity Director LeVien Boosts Stake with RSU and Options Grant

Celularity Inc. Director Vincent LeVien was granted 125,000 restricted stock units and 156,250 stock options under the company's 2021 Equity Incentive Plan.

Summary

• Vincent LeVien, a Director of Celularity Inc. (CELU), acquired 125,000 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs).
• He also acquired 156,250 stock options with an exercise price of $1.2 per share.
• Both the RSUs and stock options were granted under the Celularity Inc. 2021 Equity Incentive Plan.
• The RSUs and stock options will vest and become exercisable on the earlier of the one-year anniversary of the grant date (December 29, 2025) or the next annual stockholder meeting, contingent on Mr. LeVien's continuous service.
• The stock options have an expiration date of December 29, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of a director's interests with the company through equity grants, which is generally viewed favorably by investors as it incentivizes long-term performance. No negative information is present.

Positives

• Director Vincent LeVien received a significant grant of 125,000 Restricted Stock Units (RSUs) and 156,250 stock options, indicating continued alignment of his interests with shareholders.
• The grants are part of the Celularity Inc. 2021 Equity Incentive Plan, suggesting a structured approach to executive compensation and retention.

Negatives

• No direct negative financial or operational information is disclosed in this Form 4 filing.

Risks

• The vesting of RSUs and stock options is subject to the reporting person's continuous service with the Issuer, meaning forfeiture if service terminates before vesting.

Future Outlook

The grants of RSUs and stock options are designed to incentivize long-term commitment and performance from Director Vincent LeVien, aligning his future interests with the company's success through equity participation.

Management Comments

• No direct management comments or notable quotes are provided in this Form 4 filing.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and cell therapy industry, where equity-based compensation, such as RSUs and stock options, is commonly used to attract, retain, and motivate key directors and executives. Such compensation aligns the interests of leadership with long-term shareholder value creation, a critical aspect in a sector often characterized by long development cycles and significant capital requirements.

Comparison to Industry Standards

• Equity incentive plans, including grants of RSUs and stock options, are a common compensation tool for directors and executives across the biotechnology and pharmaceutical sectors, similar to practices at companies like Gilead Sciences or Moderna.
• The vesting schedule, tied to continuous service and a one-year anniversary or next annual meeting, is a typical structure designed to promote retention and long-term commitment, consistent with corporate governance best practices in the industry.
• The exercise price of $1.2 for the stock options, while specific to Celularity, is a standard feature of options grants, allowing the holder to benefit from future stock price appreciation above this threshold.

Related Party Transactions

• The grant of RSUs and stock options to Director Vincent LeVien constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to more focused efforts on long-term value creation.
• Employees: No direct impact on general employees is noted, but the use of an equity incentive plan suggests a broader framework for employee and executive compensation.

Next Steps

• The RSUs and stock options will vest on the earlier of the one-year anniversary of the grant date (December 29, 2025) or the next annual stockholder meeting, subject to continuous service.
• The stock options will expire on December 29, 2035.

Key Dates

Keywords

Celularity Inc., CELU, Vincent LeVien, Form 4, SEC filing, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director compensation, Insider transaction, Beneficial ownership